Crinetics Pharmaceuticals Reports $10.7M Revenue in Q1 2026, Net Loss of $127.8M

Crinetics Pharmaceuticals, Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of $10.7 million, a significant increase from $361,000 in the same period last year. This growth was primarily driven by the launch of its first commercial product, PALSONIFY™, which generated $10.3 million in product revenue. The company also recognized $428,000 in collaboration and license revenue, reflecting ongoing partnerships and licensing agreements. Despite this revenue growth, Crinetics reported a net loss of $127.8 million for the quarter, compared to a net loss of $96.8 million in the first quarter of 2025.

The company's operating expenses rose to $151.1 million, up from $111.8 million year-over-year, largely due to increased research and development costs, which reached $100.1 million, compared to $76.2 million in the prior year. The increase in R&D expenses was attributed to the advancement of clinical programs and investments in earlier-stage research initiatives. Selling, general, and administrative expenses also increased to $50.8 million from $35.5 million, reflecting the costs associated with the commercialization of PALSONIFY and the expansion of the company's operational infrastructure.

Crinetics has made notable strides in its operational metrics, with 263 unique healthcare providers prescribing PALSONIFY within the first two quarters of its launch. The company received 232 enrollment forms during the first quarter of 2026, indicating strong patient engagement. Approximately 70% of patients treated with PALSONIFY were on reimbursed therapy, suggesting favorable payer coverage. The company is also expanding its geographic reach, having submitted a marketing authorization application to Brazil’s ANVISA for PALSONIFY and achieved a positive opinion from the EMA for the treatment of acromegaly.

As of March 31, 2026, Crinetics reported total assets of $1.4 billion, up from $1.1 billion at the end of 2025, bolstered by cash and cash equivalents of $114.3 million and investment securities valued at $1.2 billion. The company’s accumulated deficit increased to $1.5 billion, reflecting ongoing investments in product development and commercialization. Looking ahead, Crinetics anticipates continued net losses as it focuses on expanding its product offerings and advancing its pipeline, which includes additional therapies targeting endocrine diseases. The company plans to fund its operations through a combination of existing capital resources, product sales, and potential future equity offerings.